Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Enzon meets the Street

ENZN reported fourth quarter 2003 operating EPS ended June 30 of $0.26, which met the Street consensus

Read the full 178 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE